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Abstract
Patients with cirrhosis who develop tense ascites and hepatorenal
syndrome have a very high mortality and present a management
challenge. Current debate stems from a lack of studies evaluating
changes in effective arterial blood volume following paracentesis or
targeting fluid replacement with appropriate vascular physiological
measures to ensure no paracentesis-related circulatory dys-
function. The study by Umgelter and colleagues addresses a goal-
directed approach to fluid management in hepatorenal syndrome
and raises several mechanistic questions, the answers to which are
likely to improve our understanding of the pathophysiology in
hepatorenal syndrome and to guide future management.
Decompensated cirrhosis is characterized by severe
circulatory derangements including progressive splanchnic
vasodilatation and portal hypertension. These derangements
result in several of the complications of advanced cirrhosis,
such as increasing ascites and hepatorenal syndrome (HRS).
The splanchnic vasodilatation in turn results in relative arterial
underfilling [1], with consequent activation of the
neurohumoral system, leading to vasoconstriction of
numerous vascular beds including the liver, the kidney and
the brain [2]. The more advanced the disease, the greater the
activation of these neurohumoral factors, most maximal in the
state of HRS [3]. Management of tense ascites in the context
of evolving HRS has been debated with the concern that a
large-volume paracentesis may evoke paracentesis-induced
circulatory dysfunction despite volume replacement, thereby
further potentiating HRS.
The study reported by Umgelter and colleagues in the
previous edition of Critical Care describes the single and
combined effects on haemodynamics and renal function of
plasma expansion with albumin and paracentesis in patients
with tense ascites and HRS [4]. Maintenance of the global
end-diastolic volume was achieved by invasive monitoring of
the central volume. The study’s key findings were a
demonstration that the cardiac index in HRS patients was
fluid responsive despite a normal central venous pressure,
and that the reduction in intra-abdominal pressure following
paracentesis was associated with an improvement in renal
function in the context of fluid substitution guided by assess-
ment of the global end-diastolic volume. In their uncontrolled
study, a transpulmonary thermodilution technique (the PiCCO
system, Pulsion Medical Systems, AG) facilitated measure-
ment of both cardiac output as well as intrathoracic and
pulmonary blood volumes. A subtraction of the pulmonary
blood volume from the intrathoracic blood volume enabled an
estimate of the ‘central’ blood volume, referred to as the
global end-diastolic volume index (GEDVI).
The authors are to be congratulated on their attention to
haemodynamic monitoring, since in cirrhosis a mismatch
exists between the capacity of the vascular system and the
volume available to fill it; that is, there is a reduced ‘effective’
arterial blood volume [5]. Given the complexity of interpreting
central venous pressure measurements in patients with
increased intra-abdominal pressure and marked systemic
vasodilatation, measurement of the central blood volume (the
pulmonary, cardiac and central arterial tree contributions) as
performed by Umgelter and colleagues is likely to reflect the
closest estimation to this effective arterial volume [4]. The
authors observed a significant early increase in the GEDVI
after a 200 ml fluid load of 20% albumin despite no
significant increase in central venous pressure and an actual
reduction in the systemic vascular resistance. It is likely that
this observation can be explained by a reduction of
endogenous vasopressors (with unopposed vasodilatation)
as a consequence of improved cardiac function, even though
vasopressor activity was not specifically measured in this
study.
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Previous studies investigating the effects of an albumin load
in Child C cirrhosis [6] and in the treatment of bacterial
peritonitis [7] have demonstrated a significant reduction in
plasma renin activity following therapy. Moreover, it has been
suggested that cirrhotic patients exist in a compensated
systemic vasodilated state, with a greater contribution of
vasoconstrictors such as noradrenaline, angiotensin II and
endothelin-1, to maintain basal vascular tone. [8] The relative
change in the balance between vasoconstrictors and
vasodilators may also explain the drop in systemic vascular
resistance observed in the study by Umgelter et al.
Another important finding of this study is the improvement in
creatinine clearance and the fractional extraction of sodium
following paracentesis, despite GEDVI subsequently increas-
ing, by adopting a ‘goal directed’ target for fluid substitution
[4]. This finding has significant clinical relevance given the
reduction in systemic vascular resistance and the previously
held concerns for potential to develop postparacentesis
circulatory dysfunction, with an aggravation of the hyper-
dynamic cirrhotic circulatory state.
Although 40 g albumin infusion does not expand the central
blood volume in patients with advanced Child C cirrhosis, a
study by Brinch and colleagues does show a significant
improvement in the low effective arterial blood volume in
these patients associated with a reduction in plasma renin
levels alongside an increase in arterial compliance, which may
be important in the prevention of circulatory dysfunction [6]. A
not too dissimilar result has been achieved using vaso-
constrictors and albumin prior to transjugular intrahepatic
portosystemic stent shunt insertion in HRS patients, with
improvement in fractional sodium excretion and renal function
associated with a reduction in plasma renin levels after 1 year
of follow-up [9]. A targeted approach to maintaining effective
arterial blood volume through an associated decrease in
activation of the renin–angiotensin mechanism will, therefore,
have a positive effect on renal dysfunction.
Another factor worthy of note is the recognition that there is
enhanced sympathetic activation with advancing liver disease –
which has been suggested to interfere with renal blood flow
autoregulation, causing increasing dependence of the renal
blood flow on the renal perfusion pressure [3]. The sug-
gested improvement in renal perfusion pressure observed by
Umgelter and colleagues may therefore not only be the effect
of reducing the intra-abdominal pressure but may also result
from the effects of decreasing sympathetic activation, even
though this was not measured in their study.
In summary, the data provided by Umgelter et al. provide
important support for a goal-directed approach to fluid
management in advanced cirrhosis and HRS, and emphasize
that the cardiac index may be fluid responsive in such
patients despite normal central venous pressure [4]. More
extensive studies, however, are required to further validate
the methodology to assess the GEDVI in cirrhotic patients
before this measure can be implemented as the standard of
care in the management of HRS.
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